A very interesting, phase I study, is ongoing, studying the effect of venetoclax added to chemotherapy in pediatric and young adult patients with any relapsed/refractory tumor type with evidence of BCL-2 expression, which will present additional data to this subject [92]. Here, BCL2 is linked to neoplasm.